Overview
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone (GH). It is one of the mildest and most selective GH-releasing peptides, with minimal impact on cortisol, prolactin, or appetite — making it popular for anti-aging and body composition protocols.
Mechanism of action
Ipamorelin selectively binds to the ghrelin/GHS-R1a receptor in the pituitary gland, triggering pulsatile GH release. Unlike GHRP-6 or GHRP-2, it does not significantly increase cortisol, ACTH, or prolactin, and has minimal effect on appetite (ghrelin mimicry is low). Often stacked with CJC-1295 for synergistic GH release.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| GH release / anti-aging | subcutaneous | 200–300 mcg | 2-3x daily | Inject on empty stomach (fasting enhances GH release). Best before bed and upon waking. 8-12 week cycles. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Phase II clinical trials demonstrated dose-dependent GH release with excellent safety profile. Animal studies show increased bone mineral density and improved body composition. Widely used in anti-aging clinics. Often combined with CJC-1295 (no DAC) for sustained GH elevation.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Ipamorelin for synergistic effects.
Legal status
Under FDA reclassification review. Previously available as a research peptide.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings. Supplier listings will be available if FDA reclassification is formalized.